The South African government is expected to announce a newly-revised AIDS-combating strategy this week with intensified prevention and treatment measures, a long-waited boost to the country’s arduous fight against the world’s most serious AIDS epidemic.
The Gauteng health department has initiated a door-to-door campaign, aimed at educating over one million residents about HIV and AIDS prevention and care.
Findings from one of the largest HIV/AIDS therapy studies conducted to date show that a specific strategy of interrupting antiretroviral therapy more than doubles the risk of AIDS or death from any cause.
Taking HIV patients off medications during periods when the disease appears to be under control is a risky – and sometimes fatal – treatment strategy, according to a large international study published in the New England Journal of Medicine.
Thailand Health Ministry has issued its first compulsory licence to make a cheaper version of Efavirenz, a life-saving medicine sold by a major international drug company, Merck & Co Inc, which holds the patent on the drug also known as Stocrin.
Results from one of the largest HIV/AIDS treatment trials ever conducted show that a specific strategy of interrupting antiretroviral therapy more than doubles the risk of AIDS or death from any cause. In the study, the investigators used two predetermined levels of CD4+ T cells, the primary immune cell targeted by HIV, to guide them in respectively suspending or restarting the study participants on antiretroviral therapy.
More people are voluntarily getting tested for HIV, worldwide. Today, the department of health, South Africa revealed that more South Africans are voluntarily getting counselled and tested for HIV with figures rising annually.
More people die from HIV/Aids every month than in the Indian Ocean tsunami, says Professor Robert Gallo, who helped identify the HIV/AIDS virus nearly 25 years ago, said the Asian tsunami killed an estimated 230,000 people.
Bristol-Myers Squibb Company (NYSE: BMY) in cooperation with the National AIDS Fund today launched the third annual “Light to Unite” campaign in support of World AIDS Day. This year’s “Light to Unite” program shines a light on the devastating impact of the HIV/AIDS epidemic in underserved communities throughout the United States. Bristol-Myers Squibb and the National AIDS Fund are encouraging people across the country to visit http://www.lighttounite.org/ to show their support and to educate themselves and others on emerging HIV/AIDS issues within diverse communities across the U.S.
On the occasion of World Aids Day 2006 Boehringer Ingelheim stated that its patent rights to Viramune (nevirapine) do not prevent access to this medication in low income countries.